Associated Papers
Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility.
Toledo RA et al.
Endocrine-related Cancer, 2015
25425582 (PubMed )
Supplement: supp_ERC-14-0491_Supplementary_table_2.xlsx › Sheet1
The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors.
Stehr H et al.
Molecular Cancer, 2011
21575214 (PubMed )
Supplement: 1476-4598-10-54-S3.XLS › mutations.txt
Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma.
Santarpia L et al.
Journal of Internal Medicine, 2009
Dysregulated RET signaling in thyroid cancer.
Castellone MD et al.
Endocrinology and Metabolism Clinics of North America, 2008
Structure and chemical inhibition of the RET tyrosine kinase domain.
Knowles PP et al.
The Journal of Biological Chemistry, 2006
Minireview: RET: normal and abnormal functions.
Santoro M et al.
Endocrinology, 2004
Dysfunction of the RET receptor in human cancer.
Santoro M et al.
Cellular and Molecular Life Sciences : Cmls, 2004
Somatic mutations in RET exons 12 and 15 in sporadic medullary thyroid carcinomas: different spectrum of mutations in sporadic type from hereditary type.
Uchino S et al.
Japanese Journal of Cancer Research : Gann, 1999
Select a paper to view details